MANAGEMENT
The Company is managed by Mr. Richard Gabriel, BS, MBA who serves as CEO/President and Director. Mr. Gabriel is supported by his staff of seasoned professionals, including Hector J. Gomez, MD, PhD, who is the company’s CMO (Chief Medical Officer) and also serves as Chairman of the Board, Tony Frudakis, PhD, CSO (Chief Scientific Officer) and also serves as a Director, and Ms. Karen Surplus,  CFO (Chief Financial Officer). Mr. Gabriel plans to add additional professionals to the company’s staff as the company grows.

Richard Gabriel, BS, MBA, CEO/ President
From 1998 until 2001 Mr. Gabriel served as Chief Executive Officer and President of Calix Corporation, parent company to Pharm-Eco Laboratories, Inc. He was one of five core team members that set the overall strategic direction for Pharm-Eco Laboratories, Inc. and helped guide Pharm-Eco's high performance self-directed organization. Mr. Gabriel was instrumental in closing and managing over $135 million in contract revenue for Pharm-Eco Laboratories and successfully completed the formation of several joint ventures, limited liability companies and spin-offs that resulted in several public and private companies in the genetics/chemistry/pharmaceutical field. From 2001 until becoming the Chief Executive Officer and President for DNAPrint®, he consulted for several start-up companies while working as a partner at Genbiomics, LLC and as head of Life Sciences Practice at Semaphore, Inc. Prior to the formation of his own consulting practice in 1985, Mr. Gabriel was a product manager for W.R. Grace. He obtained his MBA from Suffolk University's Executive MBA Program, Boston, Massachusetts, in 1985, and his B.S. in Chemistry from Ohio Dominican College, Columbus, Ohio in 1978.

Hector J. Gomez, MD, PhD, Chief Medical Officer
Dr Gomez has over twenty years of experience in the biopharmaceutical industry and has managed the development of 10 marketed drugs, mostly in the cardiovascular area. Dr. Gomez has previously served as President and CEO of Transcend Therapeutics, Inc., CEO of Zengen, Inc., Vice President of Medical Affairs for Vertex Pharmaceuticals and as an Executive Director with Ciba-Geigy Corporation. From 1979 to 1988 Dr. Gomez was a Director and Senior Director at Merck/MSDRL Corporation. He currently serves as the Chairman of the Board of Directors of DNAPrint® Genomics, Inc., PRB Pharmaceuticals, Inc. and Asia Healthcare Ltd. Dr. Gomez received an M.D. from the National University of Colombia, and a PhD from Marquette University and a Diploma in Clinical Pharmacology from Tulane University.

Tony Frudakis, PhD, Founder, Chief Scientific Officer
Dr. Frudakis founded GAFF biologic, the predecessor in interest to DNAPrint®, in 1998. He served as its President and Chief Executive Officer. Prior to founding GAFF biologic, Dr. Frudakis was a research scientist for Corixa Corporation for four years. While at Corixa he developed several new techniques for RNA fingerprinting, managed and executed high-throughput gene discovery programs for various cancers and was instrumental in the company's early success in attracting research and development partners. In all, his work has resulted in a patent portfolio for over 350 unique genes and two products. Dr. Frudakis is a Phi Beta Kappa, Magna cum laude graduate of the University of California Irvine where he received a BS degree in Biological Sciences.  Dr. Frudakis also earned a doctorate degree in molecular and cell biology from the University of California Berkeley.

Karen Surplus, CPA, MBA, Chief Financial Officer
Ms. Surplus is a certified public accountant who consulted with DNAPrint® during the last three years prior to joining DNAPrint®.  Previously, she served as CFO of Digital Fusion, Inc., an information technology company for four years where she assisted with getting the operations from cash burn of over a million dollars a month to a break even.  She was Chief Accounting Officer at Tampa-based PowerCerv Corp.; from 1995-1999 where she was instrumental in PowerCerv’s initial public offering. From 1988-1995, she held the position of Controller and Treasurer of Progress Credit Corporation, a subsidiary of Progress Energy. Ms. Surplus’ duties included selling $500 million of assets while Progress Energy withdrew from the leasing and lending arena while optimizing profit and cash. Ms. Surplus is the Chief Financial Officer of DNAPrint Genomics, Inc. Ms. Surplus  obtained  her Bachelor of Science degree with  an  emphasis  in  accounting  from  Kansas  State University, and earned an MBA degree  from  the  University of Tampa.